Inflection Point The thorniest problem in biopharmaceuticals is the growing conflict between cost-effectiveness and budget impact. In other words, we increasingly have weapons against disease that are, objectively and
No Curve today, but if you’re really jonesing for something to read, this Politico Pro piece — about the under-appreciated reality that the savings from Medicare price controls won’t necessarily
There’s a long Arc today on a detailed IRA-related argument that deserves a (more) detailed response. At least, it’s long by my standards (650 words), and I feel it’s fair
I’ve decided to give Threads another go, given that Twitter is less and less useful (if not actually harmful), and no one wants to see me put up a LinkedIn
Every day, I say: this is the day I’ll stop writing about obesity. And every day, at least for about the past week, I break that promise to myself. And
It’s kind of a quiet Monday, at least in the health policy world. Could be that it’s a holiday. It could be that our attention is focused on the horrific
ONCE AGAIN, you have a choice. You can read about the economics of obesity through analyst-driven think pieces that dive into frozen vegetable sales and the impact of Ozempic on
This journal article makes the case -- via analysis of claims data -- that patients almost never fill scripts for obesity medicines. The topline is that 10 of every 11
It’s kind of a slow day today, which has me thinking ahead to the J.P. Morgan Health Care conference in January. My thoughts are swirling around a couple of things:
Egg on my face: yesterday, I suggested that an ICER white paper, prepared for CMS as a part of the price-setting process for Eliquis and Xarelto, showed that those two